淋巴瘤资料6.pdf

Blackwell Publishing Asia Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab 1,13 1 1,14 1 2,15 2 Kensei Tobinai, Takashi Watanabe, Kazuki Tanimoto, Dai Maruyama, Masanobu Nakata, Kuniaki Itoh, Yasuo Morishima,3 3,16 4,17 5 6 7,18 Michinori Ogura, Noriko Usui, Masaharu Kasai, Takashi Terauchi, Shigeru Nawano, Masaki Matsusako,8 Yoshihiro Matsuno,9,19 Shigeo Nakamura,10 Shigeo Mori11 and Yasuo Ohashi12 1Hematology and Stem Cell Transplantation Division and 9Clinical Laboratory Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045; 2Division of Oncology and Hematology and 7Diagnostic Radiology Division, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577; 3Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681; 4 Division of Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, 3-19-18 Nishi-Shinbashi, Tokyo, 105-8471; 5Department of Internal Medicine, Sapporo Hokuyu Hospital, 6-6-5-1 Higashi Sapporo, Shiroishi-ku, Sapporo, 003-0006; 6Screening Technology and Development Division, Research Center for Cancer Prevention and Screening, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045; 8 Department of Radiology, St Lukes International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo 104-8560; 10Pathology and Clinical Laboratories, Nagoya University Hospital, 65 Tsurumai-Cho, Showa-ku, Nagoya,